FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005111569> ?p ?o ?g. }

• W2005111569 endingPage "135" @default.
• W2005111569 startingPage "129" @default.
• W2005111569 abstract "Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients and Methods Forty-nine previously untreated white patients who had stage IIIB/IV pulmonary adenocarcinoma or bronchoalveolar carcinoma and who were nonsmokers or former light smokers were treated with erlotinib 150 mg daily, irrespective of the EGFR mutation status. Results In an intention-to-treat analysis, the overall response rate (ORR) was 24.5%. The median progression-free survival (PFS) was 6.7 months, the median overall survival (OS) was 15.5 months, and the 1-year survival rate was 61.3%. Among the 36 patients for whom tumor material was available, 9 (25%) had activating EGFR mutations. The ORR was 66.7% in patients with activating EGFR mutations and 14.8% in patients with wild-type EGFR (2P = .006). In patients with activating EGFR mutations, the OS has not been reached, whereas it was 12.9 months in patients with EGFR wild type (2P = .045). Twenty-four patients had a PFS of > 6 months; 11 (45.8%) of them had EGFR wild type and 7 (29.1%) had EGFR mutation. Conclusions The selection of patients for treatment with EGFR-directed tyrosine kinase inhibitors (TKIs) should be based on mutation testing. However use of clinical (smoking status) and pathologic (adenocarcinoma) criteria may identify a subgroup of patients with advanced/metastatic NSCLC who can benefit from front-line treatment with erlotinib when mutation testing is not feasible." @default.
• W2005111569 created "2016-06-24" @default.
• W2005111569 creator A5006115495 @default.
• W2005111569 creator A5014087122 @default.
• W2005111569 creator A5021474603 @default.
• W2005111569 creator A5021554009 @default.
• W2005111569 creator A5043849331 @default.
• W2005111569 creator A5058973216 @default.
• W2005111569 creator A5072900712 @default.
• W2005111569 creator A5083377302 @default.
• W2005111569 creator A5087963010 @default.
• W2005111569 creator A5023034870 @default.
• W2005111569 date "2012-03-01" @default.
• W2005111569 modified "2023-09-27" @default.
• W2005111569 title "A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer" @default.
• W2005111569 cites W1814699096 @default.
• W2005111569 cites W1973403078 @default.
• W2005111569 cites W1975276584 @default.
• W2005111569 cites W1991406121 @default.
• W2005111569 cites W1992364688 @default.
• W2005111569 cites W1998322093 @default.
• W2005111569 cites W2012978969 @default.
• W2005111569 cites W2025037368 @default.
• W2005111569 cites W2031599610 @default.
• W2005111569 cites W2032573089 @default.
• W2005111569 cites W2043696829 @default.
• W2005111569 cites W2051786446 @default.
• W2005111569 cites W2070528305 @default.
• W2005111569 cites W2076668534 @default.
• W2005111569 cites W2090029719 @default.
• W2005111569 cites W2101329867 @default.
• W2005111569 cites W2106585301 @default.
• W2005111569 cites W2110835998 @default.
• W2005111569 cites W2111710483 @default.
• W2005111569 cites W2119248047 @default.
• W2005111569 cites W2120718661 @default.
• W2005111569 cites W2122553809 @default.
• W2005111569 cites W2127101185 @default.
• W2005111569 cites W2128059540 @default.
• W2005111569 cites W2129360604 @default.
• W2005111569 cites W2132157071 @default.
• W2005111569 cites W2134370756 @default.
• W2005111569 cites W2135192471 @default.
• W2005111569 cites W2138297714 @default.
• W2005111569 cites W2139236349 @default.
• W2005111569 cites W2139248078 @default.
• W2005111569 cites W2145230626 @default.
• W2005111569 cites W2152755651 @default.
• W2005111569 cites W2152816062 @default.
• W2005111569 cites W2155946891 @default.
• W2005111569 cites W2161821474 @default.
• W2005111569 cites W2162724777 @default.
• W2005111569 cites W2166084034 @default.
• W2005111569 cites W2248850283 @default.
• W2005111569 cites W2273115456 @default.
• W2005111569 cites W2797935920 @default.
• W2005111569 doi "https://doi.org/10.1016/j.cllc.2011.08.004" @default.
• W2005111569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22000696" @default.
• W2005111569 hasPublicationYear "2012" @default.
• W2005111569 type Work @default.
• W2005111569 sameAs 2005111569 @default.
• W2005111569 citedByCount "9" @default.
• W2005111569 countsByYear W20051115692013 @default.
• W2005111569 countsByYear W20051115692014 @default.
• W2005111569 countsByYear W20051115692015 @default.
• W2005111569 countsByYear W20051115692022 @default.
• W2005111569 crossrefType "journal-article" @default.
• W2005111569 hasAuthorship W2005111569A5006115495 @default.
• W2005111569 hasAuthorship W2005111569A5014087122 @default.
• W2005111569 hasAuthorship W2005111569A5021474603 @default.
• W2005111569 hasAuthorship W2005111569A5021554009 @default.
• W2005111569 hasAuthorship W2005111569A5023034870 @default.
• W2005111569 hasAuthorship W2005111569A5043849331 @default.
• W2005111569 hasAuthorship W2005111569A5058973216 @default.
• W2005111569 hasAuthorship W2005111569A5072900712 @default.
• W2005111569 hasAuthorship W2005111569A5083377302 @default.
• W2005111569 hasAuthorship W2005111569A5087963010 @default.
• W2005111569 hasConcept C121608353 @default.
• W2005111569 hasConcept C126322002 @default.
• W2005111569 hasConcept C143998085 @default.
• W2005111569 hasConcept C2776256026 @default.
• W2005111569 hasConcept C2778087573 @default.
• W2005111569 hasConcept C2779438470 @default.
• W2005111569 hasConcept C2780580887 @default.
• W2005111569 hasConcept C2781182431 @default.
• W2005111569 hasConcept C2909325608 @default.
• W2005111569 hasConcept C535046627 @default.
• W2005111569 hasConcept C71924100 @default.
• W2005111569 hasConceptScore W2005111569C121608353 @default.
• W2005111569 hasConceptScore W2005111569C126322002 @default.
• W2005111569 hasConceptScore W2005111569C143998085 @default.
• W2005111569 hasConceptScore W2005111569C2776256026 @default.
• W2005111569 hasConceptScore W2005111569C2778087573 @default.
• W2005111569 hasConceptScore W2005111569C2779438470 @default.
• W2005111569 hasConceptScore W2005111569C2780580887 @default.
• W2005111569 hasConceptScore W2005111569C2781182431 @default.
• W2005111569 hasConceptScore W2005111569C2909325608 @default.
• W2005111569 hasConceptScore W2005111569C535046627 @default.

• next